DDInter840 DDInter1610
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Granisetron {u} may lead to a major life threatening interaction when taken with {v} Tapentadol
Tapentadol {u} (Compound) resembles {v} (Compound) Rivastigmine
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rivastigmine
Granisetron {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Granisetron {u} (Compound) causes {v} (Side Effect) Application site irritation
Application site irritation {u} (Side Effect) is caused by {v} (Compound) Rivastigmine
Granisetron {u} may lead to a major life threatening interaction when taken with {v} Tapentadol
Tapentadol {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Rivastigmine
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pyridostigmine
Pyridostigmine {u} (Compound) resembles {v} (Compound) Rivastigmine
Granisetron {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Tapentadol
Tapentadol {u} (Compound) resembles {v} (Compound) Rivastigmine
Granisetron {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is regulated by {v} (Gene) FGFR2
FGFR2 {u} (Gene) is upregulated by {v} (Compound) Rivastigmine
Granisetron {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Pyridostigmine
Pyridostigmine {u} (Compound) resembles {v} (Compound) Rivastigmine
Granisetron {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Tapentadol
Tapentadol {u} (Compound) resembles {v} (Compound) Rivastigmine
Granisetron may lead to a major life threatening interaction when taken with Tapentadol and Tapentadol (Compound) resembles Rivastigmine (Compound)
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivastigmine (Compound)
Granisetron (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Rivastigmine (Compound)
Granisetron (Compound) causes Application site irritation (Side Effect) and Application site irritation (Side Effect) is caused by Rivastigmine (Compound)
Granisetron may lead to a major life threatening interaction when taken with Tapentadol and Tapentadol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rivastigmine (Compound)
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pyridostigmine (Compound) and Pyridostigmine (Compound) resembles Rivastigmine (Compound)
Granisetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tapentadol (Compound) and Tapentadol (Compound) resembles Rivastigmine (Compound)
Granisetron (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is regulated by FGFR2 (Gene) and FGFR2 (Gene) is upregulated by Rivastigmine (Compound)
Granisetron (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Pyridostigmine (Compound) and Pyridostigmine (Compound) resembles Rivastigmine (Compound)
Granisetron (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tapentadol (Compound) and Tapentadol (Compound) resembles Rivastigmine (Compound)